Nephrogenic Systemic Fibrosis Lawyer
Do you or a loved one need legal counsel regarding NSF or another type of Gadolinium-induced illness in The United States? LegalView’s free online NSF information resource can provide you with a wide variety of information dealing with NSF and an NSF Lawsuit, simply by clicking the links on the left side of this page. In this NSF information resource you’ll find key facts about which occupations may be particularly at risk for NSF, as well as which companies manufactured Gadolinium in the past, plus resources to help those who may have already developed NSF. In addition, LegalView’s free NSF attorney referral service can connect you with an experienced NSF law firm in The USA. If you believe you or a loved one might have a NSF case, contact a LegalView NSF lawyer now, simply by using the form below.
You can find excerpts from some of our informative content here: See below for a few examples of our Nephrogenic Systemic Fibrosis related content:
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin(TM) for Multiple Sclerosis - PipelineReview.com | Business Intelligence Center - News Articles
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company involved in the development and commercialization of cell therapies, today announced positive top-line data in an open-label Phase I/II dose escalation clinical trial of the investigational T-cell vaccine, Tovaxin™, for multiple sclerosis. ... [click for more]
Breast Cancer Gene Risk May Be Overstated - Well - Tara Parker-Pope - Health - New York Times Blog - News Articles
A doctor reviewing film from a patient’s mammogram. (CM Glover for The New York Times) The risk posed by certain gene mutations linked to breast cancer may pose less danger than previously believed, a new study shows. January 8 55 comments ... [click for more]
Bayer?s Liver Cancer, Nexavar Raises Blood Pressure - News Articles
By Anna Boyd A new study revealed that a kidney liver cancer drug called Nexavar has been shown to raise the blood pressure of patients taking it. The authors of the study appeared in the January 22 onlineissue of Lancet Oncology ... [click for more]



